Cellares bet automation could cut cell-therapy manufacturing costs 75%; raised $82M

Builds the Cell Shuttle, a factory-in-a-box that automates the end-to-end manufacturing of individualized cell therapies for pharmaceutical companies.

That automating cell-therapy manufacturing on one integrated platform, instead of today's manual process, could cut time to market by two years and costs by 75%.

$100M total raised since 2019, including an $18M Series A (2020) and an $82M Series B (2021-05-05)

Founded in 2019 by Fabian Gerlinghaus and co-founders to address a bottleneck pharma companies face industry-wide: manufacturing individualized cell therapies is a manual, labor- and time-intensive process that limits how many patients an approved therapy can actually reach.

Raised an $18M Series A in 2020 led by Eclipse Ventures. By 2021, Cellares had quadrupled its team to 40 people and reached what Gerlinghaus called 'major value inflection points' with customers and technology, prompting an $82M Series B led by new investor Decheng Capital and co-led by Eclipse, with Skyviews Life Science joining and 8VC returning, to keep developing the Cell Shuttle, then still in early design and product development.

Cell therapy manufacturing was a shared bottleneck across the industry, not a single company's problem, giving a platform play a large addressable market.

The projected cost and time savings (up to 75% cheaper, up to two years faster) were concrete enough to attract new, larger investors beyond the Series A backers.

An investor's personal motivation (Eclipse's Justin Butler losing his wife to cancer) signaled the team could recruit capital aligned with the mission, not just financial return.

Quadrupling headcount and reaching 'value inflection points' with customers before raising gave the round proof points beyond a pitch deck.

In a capital-intensive, regulated industry, the biggest opportunity can be the shared infrastructure bottleneck underneath many products, not any single product itself.

As of 2021-05-05, the Cell Shuttle was in early design and product development, targeted for readiness by 2023; Cellares had quadrupled to 40 employees over the prior year and expected to double again, with total funding at $100M since its 2019 founding, against an industry backdrop where cell therapy attracted $11 billion in funding across 600 companies in 2020.